NCT05228834 - Voxelotor Neurocognitive Function Study | Biotech Hunter

Enrollment

1

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions

Sickle Cell Disease

Interventions

DRUG

Voxelotor Only Product in Oral Dose Form

During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.

DRUG

Placebo

During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.

Trial Locations (1)

21201

University of Maryland Medical Center, Baltimore